Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

MLTX

+ Watchlist+ Portfolio

MoonLake Immunotherapeutics

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$11.25
52-Week Range
$9.46 – $23.29
Market Cap
$918.30M
P/E (TTM)
—
EPS (TTM)
-3.66
Dividend Yield
0.00%
Advanced Metrics
Price/Book
2.41
PEG Ratio
—
Return on Equity
-81.47%
Return on Assets
-36.22%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
9.13
Debt/Equity
0.27
Total Debt
$101.62M
Free Cash Flow
$-146.75M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$521.46M

Market Snapshot

About

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing nanobody-based therapies for inflammatory diseases. The company's lead candidate targets IL-17A and IL-17F cytokines, aiming to treat conditions such as hidradenitis suppurativa, psoriatic arthritis, and psoriasis. MoonLake leverages its Nanobody technology platform for novel therapeutic approaches.